BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 14694919)

  • 1. Routine drug monitoring of serum concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide do not predict clinical observations in cancer patients.
    Klepstad P; Borchgrevink PC; Dale O; Zahlsen K; Aamo T; Fayers P; Fougner B; Kaasa S
    Palliat Med; 2003 Dec; 17(8):679-87. PubMed ID: 14694919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain.
    Quigley C; Joel S; Patel N; Baksh A; Slevin M
    Palliat Med; 2003 Mar; 17(2):185-90. PubMed ID: 12701850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influences on serum concentrations of morphine, M6G and M3G during routine clinical drug monitoring: a prospective survey in 300 adult cancer patients.
    Klepstad P; Dale O; Kaasa S; Zahlsen K; Aamo T; Fayers P; Borchgrevink PC
    Acta Anaesthesiol Scand; 2003 Jul; 47(6):725-31. PubMed ID: 12803591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Day-to-day variations during clinical drug monitoring of morphine, morphine-3-glucuronide and morphine-6-glucuronide serum concentrations in cancer patients. A prospective observational study.
    Klepstad P; Hilton P; Moen J; Kaasa S; Borchgrevink PC; Zahlsen K; Dale O
    BMC Clin Pharmacol; 2004 Oct; 4():7. PubMed ID: 15461818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The oral-to-intravenous equianalgesic ratio of morphine based on plasma concentrations of morphine and metabolites in advanced cancer patients receiving chronic morphine treatment.
    Takahashi M; Ohara T; Yamanaka H; Shimada A; Nakaho T; Makoto Y
    Palliat Med; 2003 Dec; 17(8):673-8. PubMed ID: 14694918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concentrations of morphine and morphine metabolites in CSF and plasma during continuous subcutaneous morphine administration in cancer pain patients.
    Wolff T; Samuelsson H; Hedner T
    Pain; 1996 Dec; 68(2-3):209-16. PubMed ID: 9121807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine.
    Klepstad P; Kaasa S; Borchgrevink PC
    Eur J Clin Pharmacol; 2000 Jan; 55(10):713-9. PubMed ID: 10663448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy.
    Holthe M; Klepstad P; Zahlsen K; Borchgrevink PC; Hagen L; Dale O; Kaasa S; Krokan HE; Skorpen F
    Eur J Clin Pharmacol; 2002 Aug; 58(5):353-6. PubMed ID: 12185559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma morphine and glucuronide (M3G and M6G) concentrations in hospice inpatients.
    Ashby M; Fleming B; Wood M; Somogyi A
    J Pain Symptom Manage; 1997 Sep; 14(3):157-67. PubMed ID: 9291702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics of morphine and its metabolites during morphine dose titration for chronic cancer pain.
    De Gregori S; Minella CE; De Gregori M; Tinelli C; Ranzani GN; Govoni S; Allegri M; Regazzi M
    Ther Drug Monit; 2014 Jun; 36(3):335-44. PubMed ID: 24595069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid and plasma concentrations of morphine, morphine-3-glucuronide, and morphine-6-glucuronide in patients before and after initiation of intracerebroventricular morphine for cancer pain management.
    Smith MT; Wright AW; Williams BE; Stuart G; Cramond T
    Anesth Analg; 1999 Jan; 88(1):109-16. PubMed ID: 9895076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of the route of administration: a comparative study at steady state of oral sustained release morphine and morphine sulfate suppositories.
    Du X; Skopp G; Aderjan R
    Ther Drug Monit; 1999 Apr; 21(2):208-14. PubMed ID: 10217341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of morphine and its glucuronides following intravenous administration of morphine in patients undergoing continuous ambulatory peritoneal dialysis.
    Pauli-Magnus C; Hofmann U; Mikus G; Kuhlmann U; Mettang T
    Nephrol Dial Transplant; 1999 Apr; 14(4):903-9. PubMed ID: 10328468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Morphine and morphine metabolite concentrations in cerebrospinal fluid and plasma in cancer pain patients after slow-release oral morphine administration.
    Wolff T; Samuelsson H; Hedner T
    Pain; 1995 Aug; 62(2):147-154. PubMed ID: 8545139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide in serum and cerebrospinal fluid following morphine administration to patients with morphine-resistant pain.
    Goucke RC; Hackett PL; Ilett KF
    Pain; 1994 Feb; 56(2):145-149. PubMed ID: 8008404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High levels of morphine-6-glucuronide in street heroin addicts.
    Antonilli L; Semeraro F; Suriano C; Signore L; Nencini P
    Psychopharmacology (Berl); 2003 Nov; 170(2):200-4. PubMed ID: 12774191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Prospective Population Pharmacokinetic Study on Morphine Metabolism in Cancer Patients.
    Oosten AW; Abrantes JA; Jönsson S; Matic M; van Schaik RHN; de Bruijn P; van der Rijt CCD; Mathijssen RHJ
    Clin Pharmacokinet; 2017 Jul; 56(7):733-746. PubMed ID: 27815868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of old age on the disposition and antinociceptive response of morphine and morphine-6 beta-glucuronide in the rat.
    Van Crugten JT; Somogyi AA; Nation RL; Reynolds G
    Pain; 1997 Jun; 71(2):199-205. PubMed ID: 9211481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma concentrations and renal clearance of morphine, morphine-3-glucuronide and morphine-6-glucuronide in cancer patients receiving morphine.
    Somogyi AA; Nation RL; Olweny C; Tsirgiotis P; van Crugten J; Milne RW; Cleary JF; Danz C; Bochner F
    Clin Pharmacokinet; 1993 May; 24(5):413-20. PubMed ID: 8504624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of morphine-6-glucuronide antinociception after morphine treatment. Is morphine-3-glucuronide involved?
    Faura CC; Olaso JM; Cabanes CG; Horga JF
    Pain; 1996 Apr; 65(1):25-30. PubMed ID: 8826486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.